RHHBY Roche Holding Ltd

Healthcare · Drug Manufacturers - General

5 · Fair Momentum 8.0 · Strong Safe

56.63

-1.41%

About the company

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and New Zealand. The company offers pharma solutions in the therapeutic areas of anaemia, blood and solid tumors, dermatology, haematology, infectious diseases, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It also provides in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and others; diagnostic instruments; and digital health solutions. Roche Holding AG has a collaboration agreement with Excalipoint Therapeutics to evaluate EXP011 in DLL3-expressing solid tumors. The company was founded in 1896 and is based in Basel, Switzerland.

Website

2.74%

65.40%

1.55

361.0B

23.89

2.37

51.49

52-week range

56.6

low 38.2 high 60.9

Dividend deep dive

Roche Holding Ltd, a Healthcare company in the Drug Manufacturers - General industry, has a current dividend yield of 3.0%. This yield falls within its 5-year range, which spans from a low of 2.79% to a high of 3.9%, and is currently near its 5-year average of 3.27%. The company has a rating score of 6.0.

Dividend history

Roche Holding Ltd currently has a dividend streak of 0 years, indicating no consecutive annual increases. The 3-year dividend growth (CAGR) is 2.51%, while the 5-year CAGR stands at 3.43%. Annual dividend payments per share have been: $1.098 in 2014, $1.084 in 2015, $1.032 in 2016, $1.018 in 2017, $1.113 in 2018, $1.094 in 2019, $1.151 in 2020, $1.278 in 2021, $1.265 in 2022, $1.287 in 2023, $1.393 in 2024, and $1.363 in 2025. The company pays dividends annually.